The straight and narrow: a game theory model of broad- and narrow-spectrum empiric antibiotic therapy

Maya Diamant^{1,2,3} and Uri Obolski^{2,3}

¹Coller School of Managment, Tel Aviv University, Tel Aviv, Israel ²School of Public Health, Tel Aviv University, Tel Aviv, Israel ³Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel

Abstract

Physicians prescribe empiric antibiotic treatment when definitive knowledge of the pathogen 2 causing an infection is lacking. The options of empiric treatment can be largely divided into broad-3 and narrow-spectrum antibiotics. Prescribing a broad-spectrum antibiotic increases the chances of covering the causative pathogen, and hence benefits the current patient's recovery. However, prescription of broad-spectrum antibiotics also accelerates the expansion of antibiotic resistance, 6 potentially harming future patients. We analyze the social dilemma using game theory. In our game model, physicians choose between prescribing broad and narrow-spectrum antibiotics to their 8 patients. Their decisions rely on the probability of an infection by a resistant pathogen before 9 definitive laboratory results are available. We prove that whenever the equilibrium strategies 10 differ from the socially optimal policy, the deviation is always towards a more excessive use of 11 12 the broad-spectrum antibiotic. We further show that if prescribing broad-spectrum antibiotics only to patients with a high probability of resistant infection is the socially optimal policy, then 13 decentralization of the decision making may make this policy individually irrational, and thus 14 sabotage its implementation. We discuss the importance of improving the probabilistic information 15 available to the physician and promoting centralized decision making. 16

17 **1** Introduction

1

The emergence and spread of antibiotic-resistant bacteria is a significant public health problem world-18 wide [1], as antibiotic resistant infections increase mortality rates and treatment costs [2]. A proposed 19 possibility to alleviate this problem is to develop novel, broad-spectrum antibiotic drugs. However, 20 developing and producing new antibiotic drugs is a prolonged and costly process, and the production 21 rate of new antibiotics has substantially decreased over the years [3, 4]. Furthermore, high consump-22 tion of antibiotics accelerates the development of resistance, quickly rendering new drugs less effective 23 [5, 6]. Therefore, new-generation broad-spectrum antibiotic drugs are a scarce resource [7], and should 24 be administered with utmost caution. 25

This attitude is at odds with empiric antibiotic therapy - the commencement of treatment without 26 definitive diagnosis of the causative pathogen. Physicians prescribing empiric therapy thus face a 27 dilemma between administering the patients efficient initial empirical antibiotic treatment and the 28 emerging need in reducing the use of broad-spectrum drugs. Empirical treatment that ex-post matches 29 the causative pathogen, is highly important, as it reduces the mortality rate due to bacterial infections 30 [8, 9]. Naturally, a broad-spectrum drug has much higher probability for such a match, compared to 31 a narrow-spectrum drug. Thus, on one hand, the best interest of the individual patient may very well 32 be receiving broad-spectrum antibiotics. On the other hand, as mentioned above, there is a social and 33 ecological utility in minimizing the use of broad-spectrum antibiotics. Hence, the best interest of the 34

entire (potential) patients' population might be referring the broad-spectrum drug as a "weapon of
 last resort", administering it only to those patients who most likely need it.

This problem is considered a social dilemma, whose mitigation deserves awareness and collective action [10, 11]. A few studies have addressed this problem using economic models, aiming to incentivize investments in hospital infection control and development of new antibiotics [12, 13]. Other studies have analyzed the clinical aspects of this decision making problem. For example, Parra-Rodriguez et al. [14] elaborated on the information available to the physician throughout the decision process, and the possible role of decision support systems. Barash et al. [15] emphasized the importance of performing proper and non-biased analytical reasoning by the physician.

This conflict of interests is especially amenable for a game-theoretic analysis. As such, previous 44 game-theoretic studies have focused on related problems in antibiotic prescription, mostly pertaining 45 to empiric therapy of viral vs bacterial infections. For example, Evolutionary game theory was used 46 to model definitive antibiotic treatment [16], demonstrating that fast social learning may help curb 47 the overuse of antibiotics. In addition, two behavioural game theory studies showed that providing 48 patients with social information about other people's antibiotic intake[17] and eliciting empathy toward 49 future patients [18] may help to reduce antibiotic overuse in mild diseases. However, these studies did 50 not consider uncertainty regarding patient diagnoses, which is a key component in empiric therapy. 51 On the other hand, when analyzing the problem of empiric antibiotic treatment using game theory, 52 Colman et al. [19] showed that if physicians ignore long-term implications of antibiotic usage and 53 base their clinical decision only on the prior probability of bacterial infection, then administering an 54 empiric antibiotic treatment is a dominant strategy. In our previous study [20], each physician did have 55 long-term consideration regarding her own future patients, and the clinical decision was based on the 56 differential information regarding the posterior probability of bacterial infection in each patient. We 57 showed that in equilibrium, the threshold probability of antibiotic treatment is lower than the socially 58 optimal one. Nonetheless, game theory has not yet been used to address the problem of choosing 59 between broad and narrow-spectrum antibiotics. 60

In the settings of this study, each patient is infected by a resistant (R) or a susceptible (\overline{R}) bacterial 61 strain. Two types of antibiotic treatments are available: narrow-(N), and broad-spectrum (B). A 62 susceptible infection is successfully cleared by both types of antibiotics, whereas a resistant infection 63 has a substantially higher probability of clearance under treatment with the broad-spectrum antibiotic. 64 The physician, an agent acting on behalf of the patient, must decide which empiric treatment 65 should be administered. Her decision relies on partial information about the patient: the likelihood of 66 a resistant bacterial infection in a given patient before culture results are available (derived from prior 67 knowledge or clinical manifestations). 68

We assume that each physician is totally and equally committed to each of her patients' health. Therefore the monetary cost of treatment is not a factor in her decision, and she aims to maximize the cumulative utility of all of her own patients over time, given the behaviour of the other physicians. By contrast, a social planner aims to maximize the cumulative utility of all the patients (regardless of their physician) over time.

The success of the treatment depends on the drugs' effectiveness in clearing the infection – the 74 probability that the infecting pathogen is susceptible to the drug. The broad-spectrum antibiotic is 75 defined as having a higher initial effectiveness. However, each use of an antibiotic increases the future 76 resistance to it, and thus decreases its effectiveness [21, 22, 23]. In principle, each antibiotic treatment 77 also exposes the patient to risks such as treatment side effects or increased likelihood of developing 78 other, antibiotic resistant bacterial infections [24, 25, 26, 27]. Nonetheless, for simplicity, and since 79 these risks are low relative to the immediate risk of not clearing the infection, we neglect these them. 80 We start by specifying the details of the game model. We then consider the use of broad-spectrum 81 antibiotics under a socially optimal policy, which takes into consideration the entire patient popula-82 tion. This policy is compared to the level of broad-spectrum antibiotic use in the subgame-perfect 83 equilibrium, where each physician considers only the utility of her own patients. We end by discussing 84 the meaning of these results, emphasizing some practical aspects. 85

⁸⁶ 2 Model

We consider a game of n players (physicians) denoted $i \in \{1, 2, ..., n\}$. The game lasts T + 1 periods, t = 0, 1, ..., T, in which each of the players treats a single patient. The socially optimal policy will be derived by assuming that one physician treats all the patients.

As mentioned, each patient is either infected by a resistant (R) or susceptible (\overline{R}) bacterial strain. 90 The true diagnosis of resistant/susceptible infection of the patient ("H-state") is unknown to the 91 players, who only have a probabilistic information based on symptoms and immediate diagnostic tests. 92 For simplicity, a patient can either have a specific set of characteristics or not have it. For example, 93 these characteristics might be previous use of antibiotics, indication from rapid diagnostic tools and 94 so forth [23, 27, 28]. We will refer to these as a patient's "signal", which is either "high" (H with 95 probability q_H) or "low" (L with probability $q_L = (1 - q_H)$). The likelihood of resistant infection given 96 the signal H is p_H , and the likelihood given L is p_L , with $p_H > p_L$. Since the current model deals 97 with a limited horizon (the number of periods is relatively small), we assume that q_H is fixed. 98

Each player knows only the signal of her own patient. Based on this information, each player may choose one of two possible actions: to either administer broad-spectrum (B) or narrow-spectrum (N)antibiotic treatment.

We further assume that (a) due to the risk of a resistant bacterial infection, treating it is always 102 preferred to not treating it; and (b) having a susceptible bacterial infection is preferred to having 103 a resistant one, regardless of whether the treatment is with a broad or narrow drug. Thus, we can 104 define three levels of utility: r_1 , the utility (or survival rate) of patients with a resistant infection given 105 inappropriate empirical treatment; r_2 , the utility of patients with a resistant infection given appropriate 106 empirical treatment; and r_3 , the utility patients with a susceptible infection given appropriate empirical 107 treatment, where $r_3 > r_2 > r_1$ (note that the assumption regarding r_3 will not be needed later on in 108 our complete model, as explained in section 2.3). 109

This decision problem is illustrated for a single patient in the decision tree shown in figure 1, and the definitions of all relevant variables are summarized in table 1.

$i \in [1, 9, \dots, m]$	\mathbf{D}_{1}
$i \in \{1, 2,, n\}$	Players (physicians / hospitals / countries)
$j \in \{H, L\}$	Patient signal (set of symptoms, high/low probability of
	infection by a resistant bacteria)
p_j	Probability of resistant bacteria given signal $j, j \in \{H, L\}$
q_j	The probability that the patient has signal $j, j \in \{H, L\}$
B,N	Broad/narrow-spectrum antibiotic drug
r_1	Utility (or survival rate) of resistant infection given
	inappropriate empirical treatment
r_2	Utility (or survival rate) of resistant infection given
	appropriate empirical treatment
r_3	Utility (or survival rate) of susceptible infection given
	appropriate empirical treatment

Table 1: Definitions of the variables of the single-patient problem

112 2.1 Effectiveness Depletion

Each use of an antibiotic drug depletes its future effectiveness due to antibiotic resistance [21, 22, 23, 27]. We assume that each use of a drug in the current period detracts its average effectiveness in the following period by a constant depletion effect, which may vary between drugs [26]. Formally, let e_B^0, e_N^0 be the initial effectiveness levels of drugs B, N respectively, where $e_B^0 > e_N^0$ (i.e., the broadspectrum drug is more likely to be effective). We denote α_B (α_N) the marginal depletion effect of individual usage of drug B (N) on drug effectiveness.




Figure 1: The decision tree of the single-patient problem, given signal p_j . The tree root starts with a decision (white square) of whether to treat with a broad (B) or narrow (N) spectrum drug. Then, the probabilities of a patient having a resistant (R) or susceptible (\bar{R}) bacterial infection, and the relevant drug's effectiveness in clearing the infection (e_B, e_N). The definitions of relevant variables are summarized in table 1.

We assume that use of N does not deplete the effectiveness of B. However, due to cross-resistance [29], the use of B can reduce the effectiveness of N. We therefore define $I \in [0, 1]$ as the effectiveness depletion independence level: (1 - I) is the fraction of α_N subtracted from e_N^0 by each use of B. Specifically, I = 0 means that the broad-spectrum antibiotics "contain" the narrow ones, in the sense that each use of B reduces the effectiveness of both B and N (by α_B and α_N respectively); I = 1means that the use of a certain drug does not induce resistance to the other drug.

The current effectiveness-state of the entire system ("E-state") is given by the couple (t, k), where t is the current period and k is the number of patients who were treated with B in the previous periods (prior to t). The transition between E-states is determined by the players' actions and the current E-state, through the effectiveness depletion dynamics. The graph in figure 2 demonstrates the possible game states and transitions for a 2-player, 3-period game.

130 $\overset{\smile}{}$ Let $e_B^{t,k}$ be the effectiveness of B at E-state (t,k).

$$e_B^{t,k} = e_B^0 - k\alpha_B \tag{1}$$

Let $e_N^{t,k}$ be the effectiveness of N at E-state (t,k).

$$e_N^{t,k} = e_N^0 - (nt - Ik) \alpha_N$$
$$e_N^{t,k} = e_N^0 - (nt - k) \alpha_N$$
(2)

If I = 1 we get




Figure 2: The E-states and possible transitions for a 2-player, 3-period game.

132 And if I = 0 we get

$$e_N^{t,k} = e_N^0 - nt\alpha_N \tag{3}$$

¹³³ The definitions of all relevant variables are summarized in table 2.

¹³⁴ We assume a finite game, with a horizon that is sufficiently short to maintain the assumption of ¹³⁵ constant parameters as reasonable. One implication of the short horizon is that q_H remains fixed for all ¹³⁶ t. Another main implication is that even if all patients are treated with the broad-spectrum antibiotic, ¹³⁷ its effectiveness remains higher than that of the narrow-spectrum antibiotic.

¹³⁸ The initial conditions of the parameters are:

¹³⁹ Condition 1. Drug B remains more effective even if all patients receive it:

$$e_B^0 - nT\alpha_B > e_N^0 - nT(1 - I)\alpha_N$$

or equivalently
$$e_B^0 - e_N^0 > nT[\alpha_B - (1 - I)\alpha_N]$$
(4)

Corollary 1.

 $e_{B}^{t,k} - e_{N}^{t,k} > n \left(T - t\right) \left[\alpha_{B} - (1 - I) \alpha_{N}\right], \forall t = 0, ..., T$ (5)

¹⁴⁰ Condition 2. The drug N is not completely ineffective even if all patients receive it:

$$e_N^0 - nT\alpha_N > 0 \quad (\Leftrightarrow e_N^0 > nT\alpha_N) \tag{6}$$

¹⁴¹ 2.2 decision rules and strategies

A strategy of a physician is a mapping from histories (of states and actions of all the players) to actions. However, in the context of medical treatment, strategies that rely on the past behaviour of other players (both "punishments" and "rewards") seem highly implausible. For example, it is

highly unlikely that a physician will decide to prescribe broad-spectrum antibiotics to her current
patient because another physician did so in the previous period. Therefore, we shall concentrate on
Markovian strategies. Markovian strategies depend only on payoff-relevant variables, which in our
model are the states (the E-states and the partial information about the H-states). Thus, we are
interested in finding the subgame perfect equilibrium in Markovian strategies (also known as Markov
perfect equilibrium - MPE).

To check whether a combination of Markovian strategies is an equilibrium, we need only to check that each player has no incentive to deviate to another Markovian strategy. This results from the fact that given any fixed stationary Markov strategy played by the other physicians, the decision problem faced by physician i is equivalent to a Markov decision process (MDP)[30]. Thus, a best response exists in Markov strategies, and it can be found using a maximization process of dynamic programming. Therefore, we will denote strategies as Markovian, even though we do not actually limit a physician from deviating into a non-Markov strategy.

A Markov strategy is compounded of decision rules. A decision rule of a physician determines what to do in the current E-state, given the signal that he currently observes (the physician's information about the current H-state), and not on the history.

Let $d_i^{t,k} \in \{\tilde{N}, \tilde{BN}, \tilde{B}\}$ be the decision rule of player *i* in E-state (t, k). We will limit our discussion to the three possible "threshold decision rules". These threshold decision rules are not only the most intuitive, it is also easy to prove that they are the most efficient.

$$d_i^{t,k} = \tilde{N} \Rightarrow$$
 Treat any patient with N
 $d_i^{t,k} = \tilde{B} \Rightarrow$ Treat any patient with B
 $d_i^{t,k} = \tilde{BN} \Rightarrow$ Give B to patient with signal H and N to patient with signal L

We further denote by $d_{-i}^{t,k}$ the decision rule of all the other players except for *i* in E-state (t,k). This

paper concentrates on symmetric strategies, and thus we assume all the other player use the same decision rule at any E-state. When modeling asymmetric strategies, $d_{-i}^{t,k}$ can be replaced by a (n-1)tuple: $\left(d_{1}^{t,k}, d_{2}^{t,k}, ..., d_{i-1}^{t,k}, d_{i+1}^{t,k}, ..., d_{n}^{t,k}\right)$. A symmetric decision rule of a social planner in E-state (t,k)is denoted $d^{t,k}$.

Therefore a pure Markov strategy s_i of physician i is an array of (T + 1) vectors, labeled $t = 0, 1, \ldots, T$. Each vector contains player i's decision rules for all the possible E-states in period t ((nt + 1) decision rules):

$$s_{i} = \left(\underbrace{\left(d_{i}^{0,0}\right)}_{t=0}, \underbrace{\left(d_{i}^{1,0}, d_{i}^{1,1}, \dots, d_{i}^{1,n}\right)}_{t=1}, \underbrace{\left(d_{i}^{2,0}, d_{i}^{2,1}, \dots, d_{i}^{2,2n}\right)}_{t=2}, \dots, \underbrace{\left(d_{i}^{T,0}, d_{i}^{T,1}, \dots, d_{i}^{T,nT}\right)}_{t=T}\right)$$

Note that if player *i* chooses strategy s_i , not all the decision rules that it contains will necessarily be applied in the realization of the game. For example, if the current E-state is (t,k) and m > 0physicians choose *B*, the game moves to E-state (t + 1, k + m), and player *i* will not implement $\begin{pmatrix} d_i^{t+1,k}, ..., d_i^{t+1,k+m-1} \end{pmatrix}$. We denote by s_i^t the projection of s_i from period *t* onward (the "tail" of the array, starting from vector *t*).

The definitions of all the variables relevant to strategy definitions and to the payoff calculations described in the following section are summarized in table 3.

173 2.3 Payoffs Calculation

174 The immediate payoffs in E-state (t, k) are:

If player i plays B:

$$p_j \left[e_B^{t,k} r_2 + (1 - e_B^{t,k}) r_1 \right] + (1 - p_j) r_3 = p_j e_B^{t,k} (r_2 - r_1) + p_j r_1 + (1 - p_j) r_3$$

e_{B}^{0}, e_{N}^{0}	Initial effectiveness (coverage percentage) of antibiotic drug
	$B/N \ (e_B^0 > e_N^0)$
α_B, α_N	The marginal effect of individual usage of drug B/N on
	resistance development (effectiveness depletion)
t = 0, 1,, T	Time $(T+1 \text{ periods})$
$k \in \{0, 1, 2,, nT\}$	Number of patients who were treated with B in
	the previous periods.
(t,k)	The E-state of the system
$I \in [0, 1]$	Effectiveness depletion independence level. $(1 - I)$ is the
	fraction of α_N subtracted from e_N by each use of B .
	(Use of N does not deplete e_B).
	$I = 0 \Rightarrow$ Full inclusion
	$I = 1 \Rightarrow$ Independence
$e_B^{t,k}$	The effectiveness of B at E-state (t,k) . $e_B^{t,k} = e_B^0 - k\alpha_B$
$\begin{array}{c} e_B^{t,k} \\ e_N^{t,k} \end{array}$	The effectiveness of N at E-state (t,k) . $e_N^{t,k} = e_N^0 - (nt - Ik) \alpha_N$

Table 2: Definitions of the variables of the effectiveness depletion dynamics

$d_i^{t,k} \in \{\tilde{N}, \tilde{BN}, \tilde{B}\}$	The decision rule of player i in E-state (t, k) .
	$d_i^{t,k} = \tilde{N} \Rightarrow$ Treat any patient with N
	$d_i^{t,k} = \tilde{BN} \Rightarrow$ Give B to patient with signal H and N to patient with signal L
	$d_i^{t,k} = \tilde{B} \Rightarrow$ Treat any patient with B
	$d_{-i}^{t,k}$: The decision rule of the other players in E-state (t,k) .
	$d^{t,k}$: A symmetric decision rule of a social planner in E-state (t,k)
s_i	A strategy of player i .
	$s_{i} = \left(\underbrace{(d_{i}^{0,0})}_{t=0}, \underbrace{(d_{i}^{1,0}, d_{i}^{1,1}, \dots, d_{i}^{1,n})}_{t=1}, \underbrace{(d_{i}^{2,0}, d_{i}^{2,1}, \dots, d_{i}^{2,2n})}_{t=2}, \dots, \underbrace{(d_{i}^{T,0}, d_{i}^{T,1}, \dots, d_{i}^{T,nT})}_{t=T}\right)$
	$\begin{pmatrix} t=0 & t=1 & t=2 & t=T \end{pmatrix}$
s_i^t	The projection of s_i from period t onward (the "tail" of the array,
	starting from vector t).
s,s^t	Strategy profiles (complete / from period t onward). $s = (s_1,, s_n)$,
	$s^t = \left(s_1^t,, s_n^t ight).$
$u_i^{t,k}(B), u_i^{t,k}(N)$	The immediate payoff of player i at E-state (t, k) for playing B/N .
	For the purpose of MPE calculations and optimal policy comparison:
	$u_i^{t,k}(B) \equiv p_j e_B^{t,k}$, $u_i^{t,k}(N) \equiv p_j e_N^{t,k}$
$\mu\left(d_{i}^{t,k} ight)$	The conditional probability of using B given the current decision rule $d_i^{t,k}$.
	$\mu\left(d_{i}^{t,k}\right) = P\left(B\left d_{i}^{t,k}\right)\right)$
	$\mu \left(d_{i}^{t,k} \right) = P \left(B \middle d_{i}^{t,k} \right)$ $\mu \left(\tilde{N} \right) = 0, \mu \left(\tilde{BN} \right) = q_{H}, \mu \left(\tilde{B} \right) = 1$
$v_i^{t,k}\left(s^{t+1}, \left(d_i^{t,k}, d_{-i}^{t,k}\right)\right)$	The expected cumulative payoff of player i from E-state (t, k)
	onward, for a strategy profile s .
$v^{t,k}\left(s^{t+1}, d^{t,k}\right)$	The expected cumulative payoff of the social planner from E-state (t,k)
	onward, for a symmetric policy (strategy profile) s .

Table 3: Definitions of the variables in the static decision problem

If player i plays N:

$$p_j \left[e_N^{t,k} r_2 + (1 - e_N^{t,k}) r_1 \right] + (1 - p_j) r_3 = p_j e_N^{t,k} (r_2 - r_1) + p_j r_1 + (1 - p_j) r_3$$

Where $j \in \{H, L\}$ is her own patient's signal, and the other parameters are defined in table 1.

Since we are interested in comparing the the expected payoffs of different actions, we can subtract identical components from all payoffs and multiply all payoffs by a positive constant, without affecting the strategic analysis. Thus, we define the immediate payoffs in period t as follows:

179 If player i plays B:

$$u_i^{t,k}(B) \equiv p_j e_B^{t,k} \tag{7}$$

180 If player i plays N:

$$u_i^{t,k}(N) \equiv p_j e_N^{t,k} \tag{8}$$

Notice that the immediate payoff of each player depends only on his own action in the current period. The mutual influence between the players is indirect and delayed, through the depletion of e. Let $v_i^{t,k}\left(s^{t+1}, \left(d_i^{t,k}, d_{-i}^{t,k}\right)\right)$ be the expected cumulative payoff of player i from E-state (t, k) onward, for a strategy profile s. Note that the payoff depends on the strategies of the players only from this point onward (i.e. their decisions for E-state t, k and for the E-states in periods t + 1, ..., T), and on the distribution of the future patients' signals.

This expected cumulative payoff $v_i^{t,k}\left(s^{t+1}, \left(d_i^{t,k}, d_{-i}^{t,k}\right)\right)$ can be calculated recursively, starting from the E-states of period *T* and moving backward. Generally speaking, it equals the expected utility in the current E-state (with respect to the probability distribution of the patients' signals) and a probabilistic transition function to E-states in the next period:

$$\begin{split} v_i^{t,k} \left(s^{t+1}, \left(d_i^{t,k}, d_{-i}^{t,k} \right) \right) &= E \left(\text{present payoff} \right) + E \left(\text{future payoff} \right) \\ &= E_{d_i^{t,k}} \left(u_i^{t,k} \right) \\ &+ \sum_{m=0}^n P \left(m \text{ players choose } B \right) v_i^{t+1,k+m} \left(s^{t+2}, \left(d_i^{t+1,k+m}, d_{-i}^{t+1,k+m} \right) \right) \end{split}$$

The expected present payoff depends on the current E-state, the player's own decision rule in the current E-state and the distribution of patient signals:

$$E \text{ (present payoff)} = E_{d_i^{t,k}} \left(u_i^{t,k} \right)$$
$$= \sum_{j \in \{L,H\}} \left[P \left(B \middle| j, d_i^{t,k} \right) q_j p_j e_B^{t,k} + P \left(N \middle| j, d_i^{t,k} \right) q_j p_j e_N^{t,k} \right]$$
(9)

- 193 If $d_i^{t,k} = \tilde{B}$: $E_{\tilde{B}}\left(u_i^{t,k}\right) = e_B^{t,k}\left[q_H p_H + (1 q_H) p_L\right]$ 194 If $d_i^{t,k} = \tilde{BN}$: $E_{\tilde{BN}}\left(u_i^{t,k}\right) = e_B^{t,k}q_H p_H + e_N^{t,k}\left(1 - q_H\right) p_L$ 195 If $d_i^{t,k} = \tilde{N}$: $E_{\tilde{N}}\left(u_i^{t,k}\right) = e_N^{t,k}\left[q_H p_H + (1 - q_H) p_L\right]$
- Due to (??), the immediate payoff from using B is higher than N, and therefore

$$E_{\tilde{B}}\left(u_{i}^{t,k}\right) > E_{\tilde{B}N}\left(u_{i}^{t,k}\right) > E_{\tilde{N}}\left(u_{i}^{t,k}\right)$$

$$\tag{10}$$

For the purpose of calculating the expected future payoff, let $\mu\left(d_{i}^{t,k}\right)$ be the conditional probability of using *B* given the current decision rule $d_{i}^{t,k}$.

$$\mu\left(d_{i}^{t,k}\right) = P\left(B\left|d_{i}^{t,k}\right)\right)$$
$$\mu\left(\tilde{N}\right) = 0, \mu\left(\tilde{BN}\right) = q_{H}, \mu\left(\tilde{B}\right) = 1$$

¹⁹⁹ When all the players use the same decision rule in the current E-state, $d_i^{t,k} = d_{-i}^{t,k}$, the total expected ²⁰⁰ payoffs can be calculated using the following recursive equation:

$$v_{i}^{t,k}\left(s^{t+1}, \left(d_{i}^{t,k}, d_{i}^{t,k}\right)\right) = \sum_{j \in \{L,H\}} \left[P\left(B\Big|j, d_{i}^{t,k}\right) q_{j}p_{j}e_{B}^{t,k} + P\left(N\Big|j, d_{i}^{t,k}\right) q_{j}p_{j}e_{N}^{t,k}\right] + \sum_{m=0}^{n} \binom{n}{m} \mu\left(d_{i}^{t,k}\right)^{m} \left(1 - \mu\left(d_{i}^{t,k}\right)\right)^{n-m} v_{i}^{t+1,k+m}\left(s^{t+2}, \left(d_{i}^{t+1,k+m}, d_{-i}^{t+1,k+m}\right)\right)$$
(11)

And when player *i* deviates to a different decision rule, $d_i^{t,k} \neq d_{-i}^{t,k}$, we get:

$$v_{i}^{t,k}\left(s^{t+1}, \left(d_{i}^{t,k}, d_{-i}^{t,k}\right)\right) = \sum_{j \in \{L,H\}} \left[P\left(B\left|j, d_{i}^{t,k}\right) q_{j}p_{j}e_{B}^{t,k} + P\left(N\left|j, d_{i}^{t,k}\right) q_{j}p_{j}e_{N}^{t,k}\right]\right] \\ + \sum_{m=0}^{n} \left[\mu\left(d_{i}^{t,k}\right) \binom{n-1}{m-1} \mu\left(d_{-i}^{t,k}\right)^{m-1} \left(1 - \mu\left(d_{-i}^{t,k}\right)\right)^{n-m} + \left(1 - \mu\left(d_{-i}^{t,k}\right)\right) \binom{n-1}{m} \mu\left(d_{-i}^{t,k}\right)^{m} \left(1 - \mu\left(d_{-i}^{t,k}\right)\right)^{n-m-1}\right] \\ + \left(1 - \mu\left(d_{-i}^{t,k}\right)\right) \binom{n-1}{m} \mu\left(d_{-i}^{t,k}\right)^{m} \left(1 - \mu\left(d_{-i}^{t,k}\right)\right)^{n-m-1}\right] \\ \cdot v_{i}^{t+1,k+m} \left(s^{t+2}, \left(d_{i}^{t+1,k+m}, d_{-i}^{t+1,k+m}\right)\right)$$

$$(12)$$

We assume the social planner uses symmetric policies. That is, it employs an identical decision rule $d^{t,k}$ on all the current patients in E-state t, k. Therefor, the expected cumulative payoff of the social planner from E-state (t, k) onward, for a symmetric policy (strategy profile) s equals

$$v^{t,k}\left(s^{t+1}d^{t,k}\right) = nv_i^{t,k}\left(s^{t+1}, \left(d_i^{t,k}, d_i^{t,k}\right)\right)$$
(13)

205 **3** Results

The socially optimal policy and the players' strategies in Subgame-Perfect Nash-Equilibrium in Markovian strategies (MPE) can be found through backward induction.

In the last period of the game, prescribing the more effective drug regardless of the patient's signal is a dominant action - both for the social planner and for any rational individual player. Under condition 1, this dominant action is B. This claim is formalized and proven in the supplementary material (SM.4).

When continuing the backward induction process to preceding periods, finding either the MPE strategies or the socially optimal policy relies on the differences between the expected payoffs from alternative E-states onward. We focus on cases in which the medical parameters of the problem and the strategy profile of the players (or the policy of the social planner) induce the following condition:

Condition 3 (Normal-differences condition).

$$\begin{split} & \left(v_i^{t,k}\left(s^{t+1}, \left(d_i^{t+1,k}, d_{-i}^{t+1,k}\right)\right) - v_i^{t,k+1}\left(s^{t+1}, \left(d_i^{t+1,k+1}, d_{-i}^{t+1,k+1}\right)\right)\right) > 0, \\ \forall i \in \{1, ..., n\}, \forall k \in \{0, 1, ..., nT\}, t = 0, ..., T \end{split}$$

This condition implies that at any given period t, player i may gain a higher expected payoff from this point onward when having a higher effectiveness of the broad-spectrum drug.

Note that this condition is not trivial and might not apply under certain combinations of medical parameters. For instance, if $\alpha_B \ll \alpha_N$ then a physician may gain a higher utility by having a slightly lower effectiveness of *B* combined with much higher effectiveness of *N* (drug *N* becomes the scarce resource). However, these circumstances are extreme and thus are of less interest.

In addition, condition 3 may not apply due to an arbitrary or "weird" behaviour of one or more players in future periods (or a sub-optimal policy of a social planner). However, we assume all players are rational and thus utility maximizers. It can be easily shown, for example, that if I = 0 the condition applies under socially optimal policy for any medical parameters.

Therefore, we refer to this condition as "normal", and our analyses and discussion concentrates on scenarios where it holds.

228 Our first theorem states a general major result:

Under the Normal-differences condition, if the decision rule \tilde{BN} at any specific game-tree node (E-state) is part of an MPE, then it is socially optimal at this Estate as well; however, if it is socially optimal at a certain E-state, an individual player may have an incentive to deviate towards an excessive use of B.

²³⁰ For formulation and proof of Theorem 1 see the supplementary material (SM.3).

This theorem entails that whenever the MPE strategies differ from the socially optimal policy - the deviation is always towards a more excessive use (i.e. a faster depletion) of the broad-spectrum drug.

Corollary 2. The expected administration of the broad-spectrum drug, at each game-tree node (Estate), and thus in the entire game, is at least as high under the MPE as under the socially optimal policy.

An interesting special case is the fixed symmetric policy (strategy profile) of "treating a high-signal patient with B and treating a low-signal patient with N" (except for the last period, where any patient is treated with B). This policy reflects the perception that B is a "weapon of last resort". We will refer to it as the "signal-based" policy (strategy profile).

Under the signal-based policy, the difference between the expected payoffs from two adjacent Estates onwards can be presented explicitly:

$$v_{i}^{t,k}\left(s^{t+1}, \left(d_{i}^{t,k}, d_{i}^{t,k}\right)\right) - v_{i}^{t,k+1}\left(s^{t+1}, \left(d_{i}^{t,k+1}, d_{i}^{t,k+1}\right)\right) = (T-t)\left[\alpha_{B}q_{H}p_{H} - I\alpha_{N}\left(1 - q_{H}\right)p_{L}\right] + \alpha_{B}\left[q_{H}p_{H} + (1 - q_{H})p_{L}\right]$$
(14)

²⁴² For formulation and proof see claim 2 on the supplementary material (SM.5).

Thus, if we ignore the effect of the last period, we get that the Normal-differences condition will apply only if

$$\alpha_B q_H p_H \ge I \alpha_N \left(1 - q_H\right) p_L$$

²⁴³ or equivalently

229

$$\frac{\alpha_B}{\alpha_N} \cdot \frac{q_H}{1 - q_H} \cdot \frac{1}{I} \ge \frac{p_L}{p_H} \tag{15}$$

Since $0 < \alpha_B, \alpha_N, q_H, p_H, p_L < 1$, equation (15) is always true for I = 0 (full inclusion, i.e. any use of *B* depletes *N* by α_N), and for a wide range of other parameters. The most limited case is when I = 1(full independence, the use of *B* does not deplete *N*). Figure 3 illustrates the possible combinations of parameter ratios for the cases of I = 1 and I = 0.1. For a given $\frac{p_L}{p_H}$ ratio, the Normal-differences condition applies for parameter combinations (of $\frac{\alpha_B}{\alpha_N}$ and q_H) that are above the relevant $\frac{p_L}{p_H}$ curve. It demonstrates that the space of possible parameter combinations for which condition 3 holds under the "treating a high-signal patient with *B* and treating a low-signal patient with *N*" policy grows as *I* decreases.

Equation (14) enables us to simplify the conditions for MPE and socially optimal policy underlying Theorem 1, and introduce Theorem 2:




Figure 3: The normal-differences condition for the policy of treating a high-signal patient with B and treating a low-signal patient with N. The horizontal axis presents the possible values of the high-signal frequency q_H and the vertical axis presents the depletion effects ratio in log-scale, $\log_{10} \frac{\alpha_B}{\alpha_N}$. Colours represent the the values of $\frac{p_L}{p_H}$ needed to satisfy the normal condition: $\frac{\alpha_B}{\alpha_N} \cdot \frac{q_H}{1-q_H} \cdot \frac{1}{I} \geq \frac{p_L}{p_H}$. In the grey area, the left-hand side of the above expression is greater than 1 and thus the condition necessarily applies (since $\frac{p_L}{p_H} < 1$ by definition). In (a) I = 1, i.e. each use of B only reduces the effectiveness of B (by α_B); in (b) I = 0.1, i.e. each use of B reduces the effectiveness of B by α_B and of N by $0.9\alpha_N$.

If condition 3 holds, then if the "signal-based policy" is socially optimal, individual players may have an incentive to deviate towards an excessive use of B. Furthermore, if this policy is not socially optimal for a given combination of medical parameters $(e_B, e_N, \alpha_B, \alpha_N, q_H, p_H, p_L, I)$ when n = 1, it may become socially optimal as the number of patients grows, but this strategy-profile will never be an MPE.

²⁵⁵ For a formal formulation and proof of Theorem 2 see the supplementary material (SM.8).

This theorem has a significant practical meaning: the more decentralized the decision making is, the more we can expect excessive administration of the broad-spectrum drug. The game-theoretic intuition is that when a single player unilaterally deviates towards overusing the broad-spectrum drug she takes the strategies of the other players as given and only considers the future consequences for her own patients, while a centralized decision maker (social planner) considers the overall implications.

$_{261}$ 4 Discussion

We have shown that rational considerations may lead individual physicians to deviate from the socially 262 optimal policy towards over-prescription of broad-spectrum antibiotics. In real-life settings, the socially 263 optimal policy, which takes into consideration the impact of antibiotic treatment on future patients, 264 is reflected in medical guidelines for empiric antibiotic therapy (see for example [31, 32, 33]). Previous 265 works are in agreement that physicians often fail to adhere to such guidelines, resulting a much higher 266 prescription rate of antimicrobial therapy generally, and particularly of broad-spectrum antibiotics[34, 267 35]. Our analysis suggests that this behaviour should not be dismissed as a lack of knowledge or an error 268 in judgement, but may alternatively be interpreted as a deliberate, rational strategic behaviour. This 269 interpretation is consistent with previous works' findings that deviation from the guidelines towards 270 over-prescription of antibiotics in general, and specifically for broad-spectrum antibiotics, is more 271 prevalent among experienced physicians and experts [35, 36]. 272

The main focus of this work is the strategic decision making of physicians, when facing multi-273 dimensional uncertainty: uncertainty regarding the diagnosis (type of causative pathogen) of their 274 present patient, the diagnoses of other physicians' present patients, the diagnoses of future patients, 275 and uncertainty regarding the present and future decisions of the other physicians. To handle the 276 complexity of this multi-player incomplete-information stochastic game analytically, we relied on a few 277 simplifying assumptions. We assumed that the information signal presented by patients is dichoto-278 mous, and that each physician treats exactly one patient per period. Although future work may relax 279 these assumptions into more generalized settings, we believe that these will not affect the nature of 280 our conclusions, because the essence of the problem will not vanish: As long as each physician con-281 siders the future consequences of antibiotic prescription only for her own patients, and not the overall 282 implications, she may have an incentive to deviate from the socially optimal policy. In addition, we as-283 284 sumed that the frequency of the high-signal symptom, q_H is fixed throughout the game. In particular, a fixed q_H is independent of the current level of effectiveness. Future research may consider a long-285 term dependence between these variables (i.e. the probability of being infected by a resistant bacteria 286 increases as drug effectiveness declines) and thus be relevant to modelling longer game horizons. 287

Obviously, the information available to physicians and their ability to make probabilistic reasoning 288 play a major role in their decisions [15]. Physicians' decisions rely on the probability of a resistant bac-289 terial infection before definitive laboratory results are available. In our setting, this probability is either 290 relatively high, p_H , or low, p_L , depending on an information signal, which is based on patient's medical 291 symptoms, clinical settings, personal data, or the results of immediate diagnostic tests. Examining 292 the proof of Theorem 2 reveals that as p_H increases and p_L decreases, the physicians are more likely 293 to condition their decision on the signal. that is, physicians will only treat high-signal patients with 294 B while treating low-signal patients with N. Thus, improving the predictability of clinical symptoms 295 or any other available data on the current patient would result in a reduction in the administration 296 of broad-spectrum antibiotics. This conclusion supports Parra-Rodriguez et al. [14] who emphasized 297 the importance of rapid diagnostic tests (RDTs) in the ICU. We showed that these RDTs may help 298 reduce the use of broad-spectrum antibiotics even if they cannot provide certain identification of the 299 pathogen, but merely improve the probabilistic information available for the physician. Hopefully, the 300 increasing development of machine learning tools for clinical decision support systems of antibiotic 301 therapy [37, 38] will facilitate such information flow to physicians. 302

The gap between the players' strategic rational behaviour and the socially optimal policy is ex-303 pected to be particularly pronounced when a large number of patients are to be treated by many 304 independent physicians, each of them making separate and independent clinical decisions. This prob-305 lem is inherent to the decentralization of decision making, which is a common practice in medicine. A 306 key challenge under these conditions is striking a balance between centralized decision making and the 307 physician's autonomy. One possible direction is to employ methods of collaborative management and 308 consensus-based regulation of antibiotic prescribing[10]. Another recommended direction is the uptake 309 and integration of decision support systems [14], which combine the patient's personal data with en-310 vironment and population-level and data, and thus improve antibiotic choices and help implementing 311 socially optimal considerations. 312

Nevertheless, before implementing any measures intended to decrease antibiotic misuse, the management or regulator who chooses and designs these measures must take into consideration that physicians are rational players. As such, they are likely to behave in accordance with their utilities, given the new "rules of the game". It is difficult to impose the socially optimal policy. Instead, the structure of the new game should be set in such a way that the desired behaviour will also be individually rational.

Acknowledgements

The authors would like to thank Professor Dov Samet and Professor Moshe Leshno for their contributions to the long process leading to the final work presented here.

322 Funding

³²³ This study was supported by the Israel Science Foundation (ISF 1286/21).

324 **References**

- [1] Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: alarm bells are ringing. Cureus. 2017;9(6).
- [2] Dadgostar P. Antimicrobial resistance: implications and costs. Infection and drug resistance.
 2019;12:3903-10.
- [3] Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015;40(4):277.
- [4] Cheesman MJ, Ilanko A, Blonk B, Cock IE. Developing new antimicrobial therapies: are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution? Pharmacognosy reviews. 2017;11(22):57.
- [5] Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial
 consumption in human communities and the frequency of resistance. Proceedings of the National
 Academy of Sciences. 1999;96(3):1152-6.
- [6] Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta analysis of the effects of antibiotic consumption on antibiotic resistance. BMC infectious diseases.
 2014;14(1):1-25.
- [7] Cook MA, Wright GD. The past, present, and future of antibiotics. Science Translational
 Medicine. 2022;14(657):eabo7793.
- [8] Yamaga S, Shime N. Association between appropriate empiric antimicrobial therapy and mortality
 from bloodstream infections in the intensive care unit. Journal of Infection and Chemotherapy.
 2018;24(4):267-71.
- [9] Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrobial agents
 and chemotherapy. 2010;54(11):4851-63.
- [10] Krockow EM, Tarrant C, Colman AM. Prosociality in the social dilemma of antibiotic prescribing.
 Current Opinion in Psychology. 2022;44:164-9.
- [11] Ito H, Wada T, Ichinose G, Tanimoto J, Yoshimura J, Yamamoto T, et al. Social dilemma in the
 excess use of antimicrobials incurring antimicrobial resistance. Scientific Reports. 2022;12(1):1-8.
- [12] Smith DL, Levin SA, Laxminarayan R. Strategic interactions in multi-institutional epidemics of
 antibiotic resistance. Proceedings of the National Academy of Sciences. 2005;102(8):3153-8.
- ³⁵⁴ [13] Roope LS, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, et al. The challenge of ³⁵⁵ antimicrobial resistance: what economics can contribute. Science. 2019;364(6435):eaau4679.
- ³⁵⁶ [14] Parra-Rodriguez L, Guillamet MCV. Antibiotic Decision-Making in the ICU. In: Seminars in
 ³⁵⁷ Respiratory and Critical Care Medicine. vol. 43. Thieme Medical Publishers, Inc.; 2022. p. 141-9.
- ³⁵⁸ [15] Barash M, Nanchal RS. Enhancing Analytical Reasoning in the Intensive Care Unit. Critical ³⁵⁹ Care Clinics. 2022;38(1):51-67.

- [16] Chen X, Fu F. Social learning of prescribing behavior can promote population optimum of an tibiotic use. Frontiers in Physics. 2018;6:139.
- [17] Böhm R, Holtmann-Klenner C, Korn L, Santana AP, Betsch C. Behavioral determinants of
 antibiotic resistance: The role of social information. Applied Psychology: Health and Well-Being.
 2022;14(3):757-75.
- [18] Santana AP, Korn L, Betsch C, Böhm R. Promoting prosociality toward future generations in antibiotic intake. Journal of Health Psychology. 2023:13591053221149526.
- [19] Colman AM, Krockow EM, Chattoe-Brown E, Tarrant C. Medical prescribing and antibiotic
 resistance: a game-theoretic analysis of a potentially catastrophic social dilemma. PloS one.
 2019;14(4):e0215480.
- ³⁷⁰ [20] Diamant M, Baruch S, Kassem E, Muhsen K, Samet D, Leshno M, et al. A game theoretic ³⁷¹ approach reveals that discretizing clinical information can reduce antibiotic misuse. Nature com-³⁷² munications. 2021;12(1):1-13.
- ³⁷³ [21] Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP, et al. Outpatient antibiotic ³⁷⁴ use in Europe and association with resistance: a cross-national database study. The Lancet. ³⁷⁵ 2005;365(9459):579-87.
- Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption
 and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary
 hospitals data in 2014. Antimicrobial Resistance & Infection Control. 2018;7(1):1-7.
- [23] Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers
 of antibiotic resistance in humans: a systematic review. The Lancet Infectious Diseases.
 2018;18(12):e368-78.
- ³⁸² [24] Cunha BA. Antibiotic side effects. Medical Clinics of North America. 2001;85(1):149-85.
- [25] Gleckman RA, Czachor JS. Antibiotic side effects. In: Seminars in Respiratory and Critical Care
 Medicine. vol. 21. Copyright[®] 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue,
 New ...; 2000. p. 0061-70.
- [26] Chowers M, Zehavi T, Gottesman BS, Baraz A, Nevo D, Obolski U. Estimating the impact of cefuroxime versus cefazolin and amoxicillin/clavulanate use on future collateral resistance: a retrospective comparison. Journal of Antimicrobial Chemotherapy. 2022;77(7):1992-5.
- Baraz A, Chowers M, Nevo D, Obolski U. The time-varying association between previous antibiotic
 use and antibiotic resistance. Clinical Microbiology and Infection. 2022.
- [28] Lewin-Epstein O, Baruch S, Hadany L, Stein GY, Obolski U. Predicting antibiotic resistance
 in hospitalized patients by applying machine learning to electronic medical records. Clinical
 Infectious Diseases. 2021;72(11):e848-55.
- [29] Cherny SS, Nevo D, Baraz A, Baruch S, Lewin-Epstein O, Stein GY, et al. Revealing antibiotic
 cross-resistance patterns in hospitalized patients through Bayesian network modelling. Journal of
 Antimicrobial Chemotherapy. 2021;76(1):239-48.
- ³⁹⁷ [30] Puterman ML. Markov decision processes: discrete stochastic dynamic programming. John Wiley
 ³⁹⁸ & Sons; 2014.
- [31] Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases. 2021 06;73(5):e1029-44.
- Available from: https://doi.org/10.1093/cid/ciab549.

[32] Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, et al. 2018 Infectious
Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya. Clinical Infectious Diseases. 2018 11;68(1):e1-e35. Available
from: https://doi.org/10.1093/cid/ciy745.

- [33] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and
 treatment of adults with community-acquired pneumonia. An official clinical practice guideline of
 the American Thoracic Society and Infectious Diseases Society of America. American journal of
 respiratory and critical care medicine. 2019;200(7):e45-67.
- [34] Crocker A, Alweis R, Scheirer J, Schamel S, Wasser T, Levingood K. Factors affecting adher ence to evidence-based guidelines in the treatment of URI, sinusitis, and pharyngitis. Journal of
 Community Hospital Internal Medicine Perspectives. 2013;3(2):20744.
- [35] Tell D, Engström S, Mölstad S. Adherence to guidelines on antibiotic treatment for respiratory
 tract infections in various categories of physicians: a retrospective cross-sectional study of data
 from electronic patient records. BMJ open. 2015;5(7):e008096.
- [36] Stojan JN, Daniel M, Hartley S, Gruppen L. Dealing with uncertainty in clinical reasoning: A
 threshold model and the roles of experience and task framing. Medical Education. 2022;56(2):195 201.
- [37] Anahtar MN, Yang JH, Kanjilal S. Applications of machine learning to the problem of antimi crobial resistance: an emerging model for translational research. Journal of clinical microbiology.
 2021;59(7):e01260-20.
- [38] Rawson TM, Ahmad R, Toumazou C, Georgiou P, Holmes AH. Artificial intelligence can improve decision-making in infection management. Nature Human Behaviour. 2019;3(6):543-5.
- ⁴²⁶ [39] Fudenberg D, Tirole J. Game Theory Cambridge MA. MIT press Grossman S and O Hart ⁴²⁷ [1983]: "An Analysis of the Principal-Agent Problem" Econometrica. 1991;51:7-45.